AstraZeneca Pharma India Limited

ASTRAZEN

INE203A01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-04-26 am EDT			5-day change	1st Jan Change
5,415 ^INR	+1.53%		+4.70%	-1.89%

Apr. 08	AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	CI
Mar. 25	AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	CI

Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director

September 29, 2023 at 08:12 am EDT

AstraZeneca Pharma India Limited informed that Mr. Rajesh Marwaha (DIN: 01458768) shall retire as Whole-time Director of the Company with effect from the closing of business hours on September 30, 2023.

Latest news about AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	Apr. 08	CI
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	Mar. 25	CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	Mar. 11	MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	Mar. 11	CI
Astrazeneca Pharma India Limited Announces Board Changes	Feb. 19	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
AstraZeneca Pharma India Limited Announces Board Changes	Feb. 08	CI
AstraZeneca Pharma India Limited Announces Directorate Appointments	Feb. 07	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	Jan. 21	MT
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	Dec. 21	MT
India's Nifty set for muted open after steep drop	Dec. 20	RE
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)	Nov. 09	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	23-10-02	MT
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	23-09-30	CI
AstraZeneca Pharma India Limited Announces Management Changes	23-09-29	CI
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director	23-09-29	CI
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023	23-09-15	CI
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023	23-08-17	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
AstraZeneca Pharma Launches Neurofibromatosis Type 1 Drug in India	23-08-10	MT
AstraZeneca Pharma India Limited Announces Launch of Selumetinib 10 Mg and 25 Mg Capsule	23-08-09	CI
AstraZeneca Pharma India Limited Announces Executive Changes	23-07-31	CI
AstraZeneca Pharma India Limited Proposes to Declare Dividend for the Financial Year 2022-23	23-07-22	CI
AstraZeneca Gets Regulatory Nod to Import Tremelimumab (Imjudo) Concentrate	23-06-01	MT

Chart AstraZeneca Pharma India Limited

Duration

Period

More charts

Company Profile

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PHARMA INDIA LIMITED	-1.89%	1.62B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B